while semaglutide has been on the market since 2017. There was no word from Novo Nordisk on plans to file the high-dose version for approval, which clearly cuts the efficacy deficit with its main ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...

A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

Embla today announced results from a 64-week real-world study presented at the European Congress on Obesity, tracking nearly 2,700 adults in a digital GLP-1 treatment program. The study found that ...